A unifying model to explain nirmatrelvir / ritonavir's high efficacy during early treatment and low efficacy as post-exposure prophylaxis, and to predict viral rebound medrxiv.org/content/10.1101/20

Sign in to participate in the conversation
Qoto Mastodon

QOTO: Question Others to Teach Ourselves
An inclusive, Academic Freedom, instance
All cultures welcome.
Hate speech and harassment strictly forbidden.